0000000000908545

AUTHOR

Angelo Andriulli

showing 38 related works from this author

Variants of CARD15 are associated with an aggressive clinical course of Crohn's Disease. An IG-IBD Study

2005

Three major variants of the CARD15 gene confer susceptibility to Crohn's disease (CD). Whether or not these variants correlate with specific clinical features of the disease is under evaluation.We investigated the possible association of CARD15 variants with specific clinical characteristics, including the occurrence of anti-Saccharomyces cerevisiae antibodies (ASCA) and antineutrophil cytoplasmic antibodies (ANCA), in a large cohort of inflammatory bowel disease (IBD) patients and their unaffected relatives.Three hundred and sixteen CD patients (156 with positive family history), 408 ulcerative colitis (UC) patients (206 with positive family history), 588 unaffected relatives, and 205 unre…

AdultMaleNod2 Signaling Adaptor Proteindigestive systemCrohn DiseaseGene FrequencyHumansMedicineSettore MED/12 - GastroenterologiaCrohn's diseaseHepatologybiologyCrohn diseasebusiness.industryIntracellular Signaling Peptides and ProteinsGastroenterologyClinical courseMiddle Agedmedicine.diseasedigestive system diseasesPhenotypeItalyCase-Control StudiesMutationImmunologybiology.proteinColitis UlcerativeFemaleAntibodybusinessFollow-Up Studies
researchProduct

Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy

2018

Background In 2017, oral direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection became available free of charge for all HCV-RNA-positive patients, irrespective of their fibrosis stage. Aim The aim of this study was to evaluate the characteristics of HCV-related chronic liver disease (CLD) in Italy just before the introduction of DAA therapy. Patients and methods Patients with CLD were enrolled in two national surveys conducted in 2001 and in 2014. The two surveys prospectively enrolled patients aged older than 18 years referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results Out of the 12 564 patie…

MaleCirrhosisTime FactorsAdministration OralHepacivirusmedicine.disease_causeChronic liver diseaseSeverity of Illness Index0302 clinical medicineRisk FactorsOdds RatioPrevalenceMedicine030212 general & internal medicineProspective StudiesMultivariate AnalysiGastroenterologyHealth SurveyMiddle AgedViral LoadItalyRNA Viral030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLogistic ModelTime FactorGenotypeHepatitis C virusAntiviral AgentsVirus03 medical and health sciencesAge DistributionInternal medicinechronic hepatitis CHumansSex DistributionProtective FactorAgedAntiviral AgentCross-Sectional StudieHepatitis B virusHepaciviruChi-Square DistributionHepatologybusiness.industryRisk Factorchronic liver diseaseBiomarkerOdds ratioHepatitis C AntibodiesHepatitis C ChronicProtective Factorsmedicine.diseaseHealth SurveysConfidence intervaldirect-acting antiviral therapyProspective Studiehepatitis infectionCross-Sectional StudiesLogistic ModelsMultivariate AnalysisEtiologyHepatitis C AntibodiebusinessBiomarkers
researchProduct

HCV genotype 1a and 1b: Similarities and differences in clinical features, therapeutic outcome and predictors of response

2014

medicine.medical_specialtyHepatologyGenotype 1bbusiness.industryInternal medicineGastroenterologymedicinebusinessOutcome (game theory)Digestive and Liver Disease
researchProduct

The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy

2019

Background: There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim: To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods: All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results: The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, …

AdultLiver CirrhosisMaleHepatitis B virusmedicine.medical_specialtyHBsAgCirrhosisHBV reactivationHbv markersHbv reactivationPrevalenceHbv vaccinationHepacivirusChronic liver diseaseAntiviral Agents03 medical and health sciences0302 clinical medicineInternal medicinePrevalencemedicineHumansHepatitis B AntibodiesReimbursementAgedHepatitis B Surface AntigensHepatologyCoinfectionbusiness.industryGastroenterologyHCV therapyvirus diseasesHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseaseChronic HCV infection; HBV reactivation; HBV/HCV coinfection; HCV therapydigestive system diseasesHBV/HCV coinfectionItalyChronic HCV infection030220 oncology & carcinogenesisDNA ViralFemaleVirus Activation030211 gastroenterology & hepatologybusiness
researchProduct

Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes

2013

BackgroundHepatitis C virus (HCV) infects approximately 3% of the world population and is the leading cause of liver disease, impacting hepatocyte metabolism, depending on virus genotype. Hepatic metabolic functions show rhythmic fluctuations with 24-h periodicity (circadian), driven by molecular clockworks ticking through translational-transcriptional feedback loops, operated by a set of genes, called clock genes, encoding circadian proteins. Disruption of biologic clocks is implicated in a variety of disorders including fatty liver disease, obesity and diabetes. The relation between HCV replication and the circadian clock is unknown.MethodsWe investigated the relationship between HCV core…

MaleGastroenterology and hepatologyCircadian clockHepacivirusVirus ReplicationHepatitisMolecular cell biologyCellular Stress ResponsesMultidisciplinaryViral Core ProteinsQMechanisms of Signal TransductionRPeriod Circadian ProteinsMiddle AgedHepatitis CCLOCKPER2ARNTLInfectious hepatitisLiverMedicineInfectious diseasesRNA ViralFemaleResearch ArticleSignal TransductionPER1AdultHistologyFeedback RegulationGenotypeSciencePeriod (gene)DNA transcriptionViral diseasesGenome ViralBiologyCell LineCell Line TumorGeneticsHumansBiologyLiver diseasesAgedVirologyHepatocytesPeriod Circadian ProteinsGene expressionARNTL2PLoS ONE
researchProduct

Etiological factors of chronic hepatitis in Italy: a 2014 national survey.

2017

Background The last Italian prevalence survey on chronic hepatitis (CH) conducted in 2001 showed that the hepatitis C virus (HCV) was the main agent associated with CH. Aim The aim of this study was to evaluate epidemiological changes in CH occurring after 13 years. Patients and methods Enrollment of 1392 CH consecutive patients referred to 16 Italian liver units in 2014 scattered all over the country (four in the North, four in the Center, four in the South, and four in the Islands) was performed. Results The mean age of the patients was 58.3 years, with a sex ratio (male/female) of 1.5. HCV infection (also with other etiologies) continues to be the most prevalent etiology (58.1%). However…

nonalcoholic fatty liver diseaseAdultMalemedicine.medical_specialtyPediatricsTime FactorsTime FactorAdolescentHepatitis C virusmedicine.disease_causemetabolic syndrome03 medical and health sciencesYoung Adult0302 clinical medicinechronic hepatitiRisk FactorsEpidemiologyNonalcoholic fatty liver diseasemedicinePrevalenceHumansAgedHepatitis ChronicHepatitisAged 80 and overHepatologybusiness.industryRisk FactorGastroenterologyEntecavirHepatitis CHealth SurveyHepatitis BHepatitis C ChronicMiddle Agedmedicine.diseaseHealth SurveysItaly030220 oncology & carcinogenesisEtiology030211 gastroenterology & hepatologyFemalehepatitis C virus infectionbusinessHumanmedicine.drugEuropean journal of gastroenterologyhepatology
researchProduct

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis.

2010

A genome-wide association screen for primary biliary cirrhosis risk alleles was performed in an Italian cohort. The results from the Italian cohort replicated IL12A and IL12RB associations, and a combined meta-analysis using a Canadian dataset identified newly associated loci at SPIB (P = 7.9 × 10−11, odds ratio (OR) = 1.46), IRF5-TNPO3 (P = 2.8 × 10−10, OR = 1.63) and 17q12-21 (P = 1.7 × 10−10, OR = 1.38).

Liver CirrhosisOncologyCanadamedicine.medical_specialtyCirrhosisEuropean Continental Ancestry GroupLOCIPRIMARY BILIARY CIRRHOSIS; GENOME WIDE ASSOCIATION; LOCIGenome-wide association studyLocus (genetics)genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver CirrhosiBiologyBiliary Meta-Analysis as Topic Odds RatioWhite PeopleArticleGENOME WIDE ASSOCIATIONAlleles Canada European Continental Ancestry Groupprimary biliary cirrhosiPrimary biliary cirrhosisMeta-Analysis as TopicMED/12 - GASTROENTEROLOGIAIL12AInternal medicineOdds RatioGeneticsmedicineHumansAllelegenomeAlleles Canada European Continental Ancestry Group; genetics Genome Genome-Wide Association Study Humans Interferon Regulatory Factors Liver Cirrhosis; Biliary Meta-Analysis as Topic Odds RatioAllelesprimary biliary cirrhosis genome-wide meta-analysesGeneticsLiver Cirrhosis BiliaryBiliaryOdds ratiomedicine.diseasePrimary biliary cirrhosisInterferon Regulatory FactorsCohortGenome-Wide Association Study
researchProduct

Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study

2004

Summary Background : In patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels, liver fibrosis has been reported in 0–22% of cases and advanced liver disease in 5–10% of cases. Aim : To determine whether patients with persistently normal alanine aminotransferase levels clear infection after anti-viral therapy at equal or different rates from infected patients with raised alanine aminotransferase levels. Methods : Thirty-five hepatitis C virus RNA-positive patients with fibrosis at liver histology (Group 1) were matched for genotype, sex, age and histology with patients with raised alanine aminotransferase levels (Group 2). Both groups were …

medicine.medical_specialtyHepatologyCombination therapybiologybusiness.industryRibavirinHepatitis C virusGastroenterologyOdds ratiomedicine.disease_causemedicine.diseaseVirologyGastroenterologyConfidence intervalchemistry.chemical_compoundLiver diseaseAlanine transaminasechemistryFibrosisInternal medicinebiology.proteinmedicinePharmacology (medical)businessAlimentary Pharmacology & Therapeutics
researchProduct

P621 Efficacy and safety of golimumab in ulcerative colitis. Preliminary data from a multicenter Italian study

2017

medicine.medical_specialtyPancolitisTumor necrosis factorsbusiness.industryGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisGolimumab03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyPredictor variableColitismedicine.symptombusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

Experts' opinions on the role of liver biopsy in HCV infection: A Delphi survey by the Italian Association of Hospital Gastroenterologists (A.I.G.O.)

2005

Background/Aims: Liver biopsy represents the gold standard to establish a diagnosis in all liver patients, but its current position in chronic viral hepatitis is questioned. We aimed to create a consensus on best practice of use of liver biopsy in the management of chronic HCV infection. Methods: We applied the Delphi method to 12 clinical scenarios of chronic HCV infection, to assess the extent of agreement (consensus measurement) and to resolve disagreement (consensus development) on the appropriateness of liver biopsy. Results: Among 108 chosen hepatologists, 61 (56.5%) accepted to participate to the first-round survey. In four patients the majority of experts (from 61.4 to 86.2%) agreed…

medicine.medical_specialtyDelphi TechniqueBiopsyHepatitis C virusDelphi methodMEDLINEDelphi methodmedicine.disease_causeInternal medicineBiopsymedicineHumansliver biopsyProbabilityAnalysis of VarianceHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyReproducibility of ResultsHepatitis CHepatitis C Chronicmedicine.diseaseSurgeryItalyLiverLiver biopsyHCVViral diseasebusinessViral hepatitisJournal of Hepatology
researchProduct

Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial

2008

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n_696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, plus ribavirin, 1000-1200 mg/day, for 48 weeks (standard, n _237) or for 24, 48, or 72 weeks if HCV-RNA–negative at weeks 4, 8, or 12, respectively (variable, n _ 459). Sustained virologic response (SVR) was achieved in 45.1% [95% confidence interval (CI) 38.8-51.4] of the patients in the standard group and in 48.8% (CI 44.2-53.3) of the patients in the variable group (P _ 0.37). The percentages of …

AdultMalemedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsGastroenterologyDrug Administration SchedulePolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineRibavirinmedicineHumansProspective StudiesRapid Virologic Responsegenotype 1Hepatologybusiness.industryRibavirinStandard treatmentInterferon-alphavirus diseasesHepatitis CMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalSurgeryTreatment OutcomechemistryRNA ViralDrug Therapy CombinationFemalehepatitis Cbusiness
researchProduct

Forecasting liver disease burden

2018

medicine.medical_specialtyLiver diseaseHepatologybusiness.industryGastroenterologymedicineIntensive care medicinemedicine.diseasebusinessDigestive and Liver Disease
researchProduct

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to pre…

2014

Background Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. Methods mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients a…

MaleOncologyCHOPEquilibrative nucleoside transporter 1BioinformaticsDeoxycytidineCohort StudiesPancreatic ductal adenocarcinomachemistry.chemical_compoundMedicine(all)Transcription Factor CHOPbiologyDCKGeneral MedicineMiddle AgedSurvival RateDisease ProgressionAdenocarcinomaFemaleMRP1DeoxycytidineMultidrug Resistance-Associated ProteinsCarcinoma Pancreatic Ductalmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaMalignancyhENT1General Biochemistry Genetics and Molecular BiologyEquilibrative Nucleoside Transporter 1Internal medicinemedicineHumansRNA MessengerSurvival rateAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchRECPAMmedicine.diseaseGemcitabineGemcitabinechemistrybiology.proteinPancreatic ductal adenocarcinoma hENT1 CHOP MRP1 DCK RECPAMbusinessTranscription Factor CHOPCHOP
researchProduct

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

2010

The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established.Four hundred and fourteen patients received Peg-interferon alpha-2b plus 1000-1200 mg of ribavirin daily according with body weightor75 kg. Patients were randomized to standard 24 weeks (Std24) or to a 12 or 36 weeks variable treatment duration (Var12/36). In the variable treatment arm, patients with or without wk4-R were allocated to either 12 or 36 weeks duration.At treatment week 4, HCV RNA was undetectable in 262 patients (63.3%), 136 in the Std24, and 126 in the Var12/36 group (p=0.41). In patients with wk4-R, end-of-treat…

AdultMalemedicine.medical_specialtyAdolescentGenotypeAlpha (ethology)Alpha interferonHepacivirusInterferon alpha-2GastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundYoung AdultPharmacotherapyInternal medicineGenotypeRibavirinmedicineHumansIn patientPrecision MedicineAgedHepatologybusiness.industryStomachRibavirinInterferon-alphaHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsSurgerymedicine.anatomical_structurechemistryRNA ViralFemalebusinessJournal of hepatology
researchProduct

Characteristics of hepatocellular carcinoma in Italy.

1998

This study aimed to assess the main features of hepatocellular carcinoma at the time of diagnosis in Italy, particularly in relation to the presence or absence of underlying cirrhosis, hepatitis virus marker patterns, age of the subjects and alpha-foetoprotein values.A total of 1148 patients with hepatocellular carcinoma seen at 14 Italian hospitals in the 1-year period from May 1996 to May 1997 were the subjects of this prevalence study. Both newly diagnosed cases (incident cases) and cases diagnosed before May 1996 but still attending the hospitals during the study period (prevalent cases) were included.We found that 71.1% of cases were positive for hepatitis C virus antibodies but negati…

AdultLiver CirrhosisMalemedicine.medical_specialtyHBsAgCarcinoma HepatocellularHepatitis C virusmedicine.disease_causeGastroenterologyAge DistributionInternal medicineHepatitis VirusesmedicinePrevalenceHumansSex DistributionAgedHepatitisAged 80 and overHepatitis B Surface AntigensHepatologybusiness.industryIncidence (epidemiology)Liver NeoplasmsLiver cancer; risk factors; ItalyHepatitis BHepatitis C AntibodiesMiddle Agedmedicine.diseaseLogistic ModelsItalyHepatocellular carcinomaImmunologyRegression AnalysisFemalealpha-FetoproteinsLiver cancerbusinessViral hepatitisJournal of hepatology
researchProduct

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient dat…

2002

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies. Methods: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Retreatment with various IFN schedules (mean total dose 544 mega units) and a fixed ribavirin dose (1000–1200 mg/daily depending on body weight) was given for 24–60 (mean 39.5) weeks. Results: Biochemical …

HCV interferon ribavirinAdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentAlpha interferonGastroenterologyAntiviral AgentsDrug Administration Schedulechemistry.chemical_compoundDrug TherapyInternal medicineRibavirinmedicineHumansImmunologic FactorsTreatment FailureChronicAdverse effectChemotherapyAdult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy; Combination; Female; Hepatitis C; Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure; gamma-GlutamyltransferaseChi-Square Distributionbusiness.industryRibavirinLiver DiseaseGastroenterologyInterferon-alphaHepatitis Cgamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CConfidence intervalhumanitiesSurgeryLogistic ModelschemistryTolerabilityCombinationDrug Therapy CombinationFemalebusiness
researchProduct

Gross Pathologic Types of Hepatocellular Carcinoma in Italy

1999

The prevalence and independent predictors of the different macroscopic types of hepatocellular carcinoma (HCC) were assessed in 1,073 unselected patients of 14 hospitals in Italy from May 1996 to May 1997. Solitary HCC was the most common cancer type (44.6%), followed by multinodular (44.2%), diffuse (8.4%) and massive (2.8%) types. After adjustment for the influence of confounders by multiple logistic regression analysis, Child-Pugh grades B and C were found to be independent predictors of multinodular (odds ratio, OR, 2.0; 95% confidence interval (CI) = 1.5–2.6) and diffuse (OR 2.6; 95% CI = 1.6–4.4) HCC types. These findings indicate that the majority of HCC cases are not detected at a p…

MaleHCC; pathologyCancer ResearchPathologymedicine.medical_specialtyCarcinoma Hepatocellularbusiness.industryLiver NeoplasmsNodule (medicine)General MedicineMiddle Agedmedicine.diseasedigestive system diseasesGross examinationLogistic ModelsItalyOncologyHepatocellular carcinomaPrevalenceHumansMedicineFemaleHepatitis Antibodiesmedicine.symptombusinessOncology
researchProduct

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

2017

Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child…

MaleCirrhosisSettore MED/09 - Medicina InternaAlcohol abuseAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Internal Medicinemedicine.disease_causeGastroenterology0302 clinical medicineRisk FactorsEpidemiologyHBV030212 general & internal medicineLiver Neoplasmsvirus diseasesMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver NeoplasmHepatocellular carcinomaHCV030211 gastroenterology & hepatologyAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Aged; Alcoholism; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Internal MedicineFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusLiver CirrhosiAlcohol abuseLiver cirrhosis epidemiology03 medical and health sciencesInternal medicinemedicineInternal MedicineHumansDecompensationAgedHepatitis B virusCross-Sectional Studiebusiness.industryRisk FactorCarcinomaHepatocellularmedicine.diseaseCross-Sectional StudiesLiver cirrhosisEtiologybusiness
researchProduct

Anticardiolipin antibodies in patients with liver disease.

1999

OBJECTIVE: Our aim was to test the hypothesis that anticardiolipin antibodies (aCL) may cause an antiphospholipid syndrome and thrombotic events in patients with liver disease. METHODS: aCL were measured in 116 healthy controls and 372 patients with liver disease of different stage and etiology: 136 cases secondary to hepatitis C virus (HCV) infection, 139 due to hepatitis B virus (HBV) infection, 69 with alcoholic liver damage, and 28 cryptogenic in origin. Prior thrombotic events were recorded. The results were related to age, gender, stage, severity, and etiology of the liver disease, as well as to the occurrence of organ- and nonorgan-specific autoantibodies. RESULTS: aCL were positive …

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseasemedicine.disease_causeGastroenterologyLiver diseaseHepatitis B ChronicAntiphospholipid syndromeInternal medicinemedicineHumansAutoantibodiesHepatitis B virusHepatologybusiness.industryLiver DiseasesGastroenterologyMuscle SmoothThrombosisOdds ratioHepatitis CHepatitis C ChronicMiddle AgedHepatitis BAntiphospholipid Syndromemedicine.diseaseLogistic ModelsAntibodies AnticardiolipinHepatocellular carcinomaChronic DiseaseImmunologyFemalebusiness
researchProduct

Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin

2008

Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peg-interferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. The aim of this study was to delineate patient characteristics that might help to identify individuals likely to benefit from ribavirin discontinuation. One hundred and forty-four HCV-2- and HCV-3-infected patients initiated Peg-IFN alpha-2a (180 microg/week) and ribavirin (1000 or 1200 mg/day); those with viral clearance at week 4 were randomized …

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeChronic hepatitis CAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundVirologyInternal medicineRibavirinmedicineHumansRapid Virologic ResponseHepatologyPeg-interferonbusiness.industryRibavirinInterferon-alphavirus diseasesHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CRecombinant Proteinsdigestive system diseasesDiscontinuationClinical trialTreatment OutcomeInfectious DiseasesWithholding TreatmentchemistryImmunologyChronic hepatitis C; Clinical trial; Peg-interferon; Ribavirin;FemaleViral hepatitisbusinessViral load
researchProduct

Neoadjuvant Chemo-Radiotherapy for Patients with Borderline Resectable Pancreatic Cancer: A Meta-Analytical Evaluation of Prospective Studies

2012

Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therapy remains to be defined. Objective We did a systematic search of the literature on this topic. Methods Prospective studies, where chemotherapy, irrespective of regimen, in combination with radiotherapy was given before surgery to patients with borderline resectable cancer, were analyzed by a meta-analytical method. Primary outcome was tumor response; surgical exploration rate, resection rate, therapy-induced toxicity, and survival were secondary outcomes. Data were expressed as weighted pooled proportions with 95% confidence interval (95% CI). Results Eleven studies with 247 participants were…

Oncologymedicine.medical_specialtyChemo-radiotherapyMeeting Abstracts; PancreasHepatologybusiness.industryEndocrinology Diabetes and MetabolismGastroenterologymedicine.diseaseBorderline resectablePancreatic cancerInternal medicinemedicinebusinessProspective cohort study
researchProduct

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

2009

Efficacy of retreatment with pegylated interferon (PEG-IFN) plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and factors influencing efficacy and tolerability still remain incompletely defined. We aimed to focus on SVR rates and to identify factors influencing them in this meta-analysis.MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncontrolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated IFN and ribavirin therapy. Fourteen trials were included in t…

medicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinvirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalTolerabilitychemistryMeta-analysisInterferon Type IImmunologyDrug Therapy Combinationbusinessmedicine.drugJournal of Hepatology
researchProduct

Smoking as a cofactor for causation of chronic pancreatitis: a meta-analysis.

2010

Objectives To assess the evidence for tobacco smoking as a risk factor for the causation of chronic pancreatitis. Methods We performed a meta-analysis with random-effects models to estimate pooled relative risks (RRs) of chronic pancreatitis for current, former, and ever smokers, in comparison to never smokers. We also performed dose-response, heterogeneity, publication bias, and sensitivity analyses. Results Ten case-control studies and 2 cohort studies that evaluated, overall, 1705 patients with chronic pancreatitis satisfied the inclusion criteria. When contrasted to never smokers, the pooled risk estimates for current smokers was 2.8 (95% confidence interval [CI], 1.8-4.2) overall and 2…

medicine.medical_specialtyAlcohol DrinkingEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRisk AssessmentEndocrinologyRisk FactorsInternal medicinePancreatitis ChronicInternal MedicinemedicineOdds RatioHumansRisk factorHepatologybusiness.industrySmokingOdds ratiomedicine.diseaseConfidence intervalSurgerysmoking chronic pancreatitisRelative riskSmoking cessationPancreatitisRisk assessmentbusinessCohort study
researchProduct

Combination therapy with amantadine and interferon in naı̈ve patients with chronic hepatitis C: meta-analysis of individual patient data from six cli…

2003

Abstract Background/Aims In chronic hepatitis C, clinical trials evaluating the efficacy of amantadine (AMA) and interferon (INF) compared to INF monotherapy, have produced conflicting results. We performed a meta-analysis of the individual patient's data from previous studies. Methods Nine hundred and seventy-two patients from six European centres were evaluated by means of individual patient meta-analysis, using mixed models with centres and the centre–treatment interaction fitted as random variables. Results At the end of therapy, virological responses were 38.5% (95% CI 34.1–42.8) after INF and AMA, and 29.5% (95% CI 25.5–33.6) after INF alone (P=0.003). Sustained response occurred in 1…

AdultMalemedicine.medical_specialtyGenotypeCombination therapyHepacivirusAntiviral AgentsGastroenterologymeta-analysilaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled triallawInternal medicineparasitic diseasesAmantadinemedicinechronic hepatitis CHumansAgedRandomized Controlled Trials as TopictherapyDose-Response Relationship DrugHepatologybusiness.industryRibavirinAmantadineAlanine TransaminaseinterferonHepatitis CHepatitis C ChronicMiddle AgedViral Loadrandomized clinical trialmedicine.diseaseClinical trialTreatment OutcomechemistryImmunologyDrug Therapy CombinationFemaleInterferonsbusinessViral loadmedicine.drugJournal of Hepatology
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin.

2014

Background & Aims The pool of HCV genotype 1 patients likely to be cured by peg-interferon and ribavirin remains to be quantified. Methods In 1045 patients treated with peg-interferon and ribavirin, two therapeutic strategies were confronted: the first one evaluated only baseline variables associated with sustained virological response (SVR), and the second one included the rapid virologic response (RVR) in addition to baseline predictors. An 80% SVR rate was the threshold to retain a strategy as clinically relevant. Results Overall, 414 patients (39.6%) attained SVR. In the first strategy, the hierarchy of features independently associated with SVR was IL28B CC genotype (OR 5.082; CI 3.637…

MaleIL28BChronic HCV liver diseaseHepacivirusGastroenterologyPolyethylene GlycolsVirological responseresponse predictorschemistry.chemical_compoundantiviral therapyGenotypeViralChronicchronic hepatitis C; antiviral therapy; response predictorsSettore MED/12 - Gastroenterologiavirus diseasesMiddle AgedHepatitis CRecombinant ProteinsCombinationHCVFemalePredictors of response; Ribavirin; Peg-interferon; HCV; Chronic HCV liver diseaseAdultmedicine.medical_specialtyGenotypeChronic HCV liver disease; HCV; Peg-interferon; Predictors of response; Ribavirin; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; RNA Viral; Recombinant Proteins; Ribavirin; HepatologyPredictors of responseViremiaAntiviral AgentsDrug TherapyChronic hepatitisInternal medicineRibavirinmedicinechronic hepatitis CHumansDual therapyRapid Virologic ResponseAgedgenotype 1Peg-interferonHepatologybusiness.industryRibavirinInterferon-alphamedicine.diseasedigestive system diseasesSurgeryPeg interferonPegIFNchemistryRNAbusiness
researchProduct

X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis

2021

Background & aims: Genome-wide association studies in primary biliary cholangitis (PBC) have failed to find X chromosome (chrX) variants associated with the disease. Here, we specifically explore the chrX contribution to PBC, a sexually dimorphic complex autoimmune disease. Methods: We performed a chrX-wide association study, including genotype data from 5 genome-wide association studies (from Italy, United Kingdom, Canada, China, and Japan; 5244 case patients and 11,875 control individuals). Results: Single-marker association analyses found approximately 100 loci displaying P < 5 × 10-4, with the most significant being a signal within the OTUD5 gene (rs3027490; P = 4.80 × 10-6; odds…

Canadian-US PBC Consortium0301 basic medicineMaleLinkage disequilibriumGenome-wide association studyDiseasePBCSettore MED/03 - GENETICA MEDICALinkage Disequilibrium0302 clinical medicineUK-PBC ConsortiumGenotypeMitochondrial Precursor Protein Import Complex ProteinsItalian PBC Genetics Study GroupOdds RatioX-Wide Association StudyJapan PBC-GWAS ConsortiumX chromosomeGeneticsLiver Cirrhosis BiliaryGastroenterologyForkhead Transcription FactorsDNA-Binding ProteinsShal Potassium Channels030211 gastroenterology & hepatologyFemaleAdultMonosaccharide Transport ProteinsSuperenhancerLocus (genetics)Single-nucleotide polymorphismBiologyProtein Serine-Threonine KinasesPolymorphism Single NucleotideArticleWhite People03 medical and health sciencesAsian PeopleProto-Oncogene ProteinsEndopeptidasesHumansCell LineageGenetic Predisposition to DiseaseMeta-analysiGenetic associationChromosomes Human XGastroenterology & HepatologyHepatology1103 Clinical SciencesMeta-analysis030104 developmental biologyGenetic Loci1114 Paediatrics and Reproductive MedicineMeta-analysis; Superenhancer; X-Wide Association Study1109 NeurosciencesCarrier ProteinsGenome-Wide Association Study
researchProduct

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.

2016

Abstract Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent …

Liver CirrhosisCirrhosisBleeding; Cirrhosis; Hemostasis; Thrombosis; Hepatology; GastroenterologySettore MED/09 - Medicina InternaBleeding; Cirrhosis; Hemostasis; Thrombosis; Anticoagulants; Coagulants; Drug Monitoring; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Postoperative Hemorrhage; Thrombosis; Blood Coagulation Tests; Hemostasis; Hepatology; Gastroenterology0302 clinical medicineEsophageal and Gastric VariceBlood coagulation testConsensus conferenceGastroenterologyThrombosisOptimal managementCirrhosisCoagulant030220 oncology & carcinogenesisThrombosi030211 gastroenterology & hepatologyBlood Coagulation TestsDrug MonitoringGastrointestinal HemorrhageHumanmedicine.medical_specialtyLiver CirrhosiBleeding; Cirrhosis; Hemostasis; Thrombosis; Gastroenterology; HepatologyPostoperative HemorrhageEsophageal and Gastric VaricesNO03 medical and health sciencesInternal medicinemedicineHumansIn patientIntensive care medicineHemostasisCirrhosiHepatologybusiness.industryCoagulantsBleeding; Cirrhosis; Hemostasis; ThrombosisBleedingAnticoagulantAnticoagulantsThrombosisHepatologyHemostasiBlood Coagulation Testmedicine.diseaseSurgeryHemostasisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance

2013

Background & Aims In patients with chronic HCV-1 infection, recent evidences indicate that determination of a dinucleotide polymorphism (ss469415590, ΔG/TT) of a new gene, designated IFN λ-4, might be more accurate than the 12979860CC type of the IL28B locus in predicting sustained virological response (SVR) following peg-interferon and ribavirin. In addition, combined genotyping of different SNPs of the IL28B locus was shown to help dissect patients most prone to SVR among those with rs12979860CT. We examined whether single or combined genotyping of two IL28B SNPs, rs12979860 and rs8099917, and ss469415590 variation might improve the prediction of SVR. Results In the study cohort of 539 pa…

MaleOncologySettore MED/09 - Medicina InternaIL28Bpeg-interferonBioinformaticsPolyethylene GlycolLinkage DisequilibriumPolyethylene GlycolsCohort StudiesIL28B/interferon lambda-3 genechemistry.chemical_compoundGene Frequencypeg-interferon/ribavirinvirus diseasesRecombinant ProteinMiddle AgedViral LoadHepatitis CRecombinant ProteinsTreatment OutcomeHCVCohortFemaleHumanAdultmedicine.medical_specialtyinterferon lambda-3 geneLocus (genetics)Single-nucleotide polymorphismBiologychronic hepatitiInternal medicineRibavirinmedicineHumansSNPAlleleGenotypingGeneinterferon lambda-4 geneAgedPolymorphism GeneticHepatologyInterleukinsRibavirinInterferon-alphaInterleukindigestive system diseaseschemistryInterferonsCohort StudieLiver International
researchProduct

An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.

2014

none 29 no Background: Aim was to select naïve patients with genotype 1 chronic hepatitis C having a high probability of response to Peg-interferon. +. ribavirin therapy. Methods: In 1073 patients (derivation cohort), predictors of rapid and sustained virological response were identified by logistic analysis; regression coefficients were used to generate prediction models for sustained virological response. Probabilities at baseline and treatment week 4 were utilized to develop a decision rule to select patients with high likelihood of response. The model was then validated in 423 patients (validation cohort). Results: In the derivation cohort, 257 achieved rapid virological response and 8…

OncologyMaleHepacivirusPredictive Value of Testchronic hepatitis C; prediction model of response; peginterferon plus ribavirin dual therapyHepacivirusPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundGenotypeViralChronicRapid virological responseDrug CarrierChronic hepatitisSettore MED/12 - GastroenterologiaDrug CarriersbiologyGastroenterologyRecombinant ProteinMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsHCV infectionTreatment OutcomePredictive value of testsCombinationRNA ViralDrug Therapy CombinationFemaleChronic hepatitis; HCV infection; Peg-interferon and ribavirin treatment; Predictors of sustained virological response rapid virological response; Adult; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Prognosis; RNA Viral; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load; Hepatology; GastroenterologyViral loadHumanAdultmedicine.medical_specialtyGenotypePrognosiAlpha interferonPredictors of sustained virological response rapid virological responseReal-Time Polymerase Chain ReactionAntiviral AgentsDrug TherapyPredictive Value of TestsInternal medicinePredictors of sustained virological responseLinear regressionRibavirinmedicinechronic hepatitis CHumansAntiviral AgentHCV infection; Predictors of sustained virological response Rapid virological response; Peg-interferon and ribavirin treatment; Chronic hepatitisHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C Chronicbiology.organism_classificationchemistryImmunologyChronic hepatitiRNAprediction model of responsepeginterferon plus ribavirin dual therapybusinessPeg-interferon and ribavirin treatmentDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.

2021

[BACKGROUND & AIMS] Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intra-hepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening. [METHODS] We combined new and existing genotype data for 10, 516 cases and 20, 77…

Liver CirrhosisALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC0301 basic medicineCandidate geneALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC; Genome-Wide Association Study; Humans; Liver Cirrhosis BiliaryItalian PBC Study GroupLD SCORE REGRESSIONJapan-PBC-GWAS ConsortiumGenome-wide association studyLocus (genetics)DiseaseSUSCEPTIBILITYPBCChronic liver diseaseBioinformaticsGENETIC ASSOCIATION1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineUK-PBC ConsortiumGenotypeHumansMedicineNetwork-based in silico drug efficacy screeningGenetic associationScience & TechnologyGastroenterology & HepatologyHepatologyLiver Cirrhosis Biliarybusiness.industryBiliaryChinese PBC Consortium1103 Clinical SciencesALSPACmedicine.diseasePBC Consortia030104 developmental biologyMeta-analysisERN RARE LIVER030211 gastroenterology & hepatologyGenomic co-localizationUK-PBCUS PBC ConsortiumERN RARE-LIVERCanadian PBC ConsortiumbusinessLife Sciences & BiomedicineGenome-Wide Association StudyHuman
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized contr…

2009

Radiofrequency thermal ablation (RF) and percutaneous ethanol injection (PEI) have been employed in the treatment of small hepatocellular carcinoma (HCC) as curative treatments. The aim of the study was to review the available evidence comparing RF to PEI for small HCC.Cochrane, MEDLINE, CANCERLIT, and ENBASE databases were used.randomized clinical trials evaluating RF vs. PEI. Data were extracted from each randomized controlled trial (RCT). Primary outcomes were overall survival and local recurrence. Meta-analysis software was used and risk differences (RDs) and their 95% confidence intervals and Q-test for heterogeneity were calculated.Five RCTs were identified including 701 patients. The…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentThermal ablationUrologyCatheter ablationInjections Intralesionallaw.inventionRandomized controlled triallawmedicineHumansSurvival rateRandomized Controlled Trials as TopicHepatologyEthanolbusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseSurgerySurvival RateTreatment OutcomeMeta-analysisHepatocellular carcinomaCatheter AblationSolventsPercutaneous ethanol injectionbusinessThe American journal of gastroenterology
researchProduct

Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis

2017

Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…

Genetics and Molecular Biology (all)0301 basic medicineLiver CirrhosisRNA virusesMaleChronic HepatitisCirrhosislcsh:MedicineAlcohol abuseHepacivirusSex FactorChronic liver diseasemedicine.disease_causeBiochemistryGastroenterologyChronic Liver Disease0302 clinical medicineRisk FactorsMedicine and Health Scienceslcsh:SciencePathology and laboratory medicineMultidisciplinaryAlcohol ConsumptionHepatitis C virusLiver DiseasesFatty livervirus diseasesHepatitis CHepatitis BMedical microbiologyMiddle AgedHepatitis BHepatitis CCirrhosisOncologyVirusesCoinfection030211 gastroenterology & hepatologyFemalePathogensResearch ArticleHumanAdultmedicine.medical_specialtyHepatitis B virusAlcohol DrinkingLiver CirrhosiGastroenterology and HepatologyMicrobiologyCarcinomas03 medical and health sciencesSex FactorsInternal medicineGastrointestinal TumorsmedicineHumansNutritionAgedHepatitis B virusBiochemistry Genetics and Molecular Biology (all)Flavivirusesbusiness.industryRisk Factorlcsh:ROrganismsViral pathogensBiology and Life SciencesCancers and NeoplasmsHepatocellular Carcinomamedicine.diseaseVirologydigestive system diseasesHepatitis virusesAdult; Aged; Alcohol Drinking; Female; Hepatitis B; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)DietMicrobial pathogensFatty Liver030104 developmental biologyAgricultural and Biological Sciences (all)lcsh:Qbusiness
researchProduct

Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

2017

Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014). Methods: The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely t…

Alcoholic liver diseasePathologyCirrhosisliver diseasesHepatocellular carcinomaPrevalenceChronic liver diseaseGastroenterology0302 clinical medicinecohort studiesEpidemiologymiddle aged030212 general & internal medicinehumansChronic liver diseasesHBV infectionChronic hepatitisadultChronic liver diseaseGeneral MedicineHepatitis CHepatitis BHCV infectionagedInfectious DiseasesItalyyoung adult030211 gastroenterology & hepatologyCohort studyMicrobiology (medical)medicine.medical_specialtyprevalence03 medical and health sciencesInternal medicinemedicineLiver Diseases AlcoholicAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinoma; Microbiology (medical); Infectious DiseasesAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinomabusiness.industryAlcoholic liver diseaseAlcoholic liver diseasesmedicine.diseaseprospective studiessex factorsChronic hepatitihepatitis Bhepatitis Cbusinesschronic diseasealcoholic liver diseases; chronic hepatitis; chronic liver diseases; HBV infection; HCV infection; hepatocellular carcinoma; adult; aged; chronic disease; cohort studies; hepatitis B; hepatitis C; humans; Italy; liver diseases; liver diseases alcoholic; middle aged; prevalence; prospective studies; sex factors; young adultalcoholic
researchProduct

ROLE OF NAKED CUTICLE HOMOLOG 1 GENE ON CHR 16Q12 IN INFLAMMATORY BOWEL DISEASE.

2010

Settore MED/38 - Pediatria Generale E SpecialisticaIBD Genetics
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct